Keywords: Cariovascular market, AstraZeneca, Novo Nordisk, Briklinta, Onglyza
Big pharma struggles to benefit from increased CVD drug usage in market set to grow to $107 billion in 2018
Article | 03 March 2010
Pharmaceutical companies will struggle to profit from the cardiovascular disease (CVD) market over the next decade, despite growing drug usage, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
